Largest childhood preventative health initiative in nearly 20 yearsBeyfortus rollout to ensure all babies are RSV protected this winterThe largest ...

Roughly 5,800 hospitalisations from bronchiolitis were avoided in France thanks to the new preventive medicine nirsevimab, Public Health France said on Friday. The health agency cited two studies ...

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

Vaccine sales increased by 5.6% to 1.2 billion euros, driven by strong Beyfortus (RSV vaccine) uptake partly offset by the absence of COVID-19 vaccine sales this quarter compared to 167 million ...

The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...